Overview

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Status:
Completed
Trial end date:
2017-10-31
Target enrollment:
Participant gender:
Summary
Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beni-Suef University
Treatments:
Simeprevir
Sofosbuvir